Incorporación de parámetros bioquímicos y algoritmos diagnósticos en el sistema informático de laboratorio para la detección precoz de alteraciones lipídicas desde las unidades de lípidos

Townsend, 2015, Cardiovascular disease in Europe–epidemiological update 2015, Eur Heart J, 36, 2696, 10.1093/eurheartj/ehv428 Instituto Nacional de Estadística [consultado julio 2020]. Disponible en: https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736176780&menu=resultados&idp=1254735573175#!tabs-1254736194710. Núñez-Cortés, 2011, Documento de abordaje de la dislipidemia. Sociedad Española de Arteriosclerosis (parte I), Clin Invest Arterioscl, 23, 278 Cooney, 2009, SCORE Investigators. Re-evaluating the Rose approach: Comparative benefits of the population and high-risk preventive strategies, Eur J Cardiovasc Prev Rehabil, 16, 541, 10.1097/HJR.0b013e32832b38a1 Arango, 2012, Biomarcadores para la evaluación de riesgos para la salud humana, Rev Fac Nac Salud Pública., 30, 75 Wilson, 2004, Assessing coronary heart disease risk with traditional and novel risk factors, Clin Cardiol., 27 Albert, 2003, Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score, Circulation., 108, 161, 10.1161/01.CIR.0000080289.72166.CF Ference, 2018, Impact of lipids on cardiovascular health: JACC Health Promotion Series, J Am Coll Cardiol, 72, 11411156 Nordestgaard, 2010, European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: Current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386 Erqou, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063 Baltodano, 2004, Guías para la prevención primaria de la enfermedad cardiovascular ateroesclerótica empezando desde la niñez, Rev Costarric Cardiol, 6, 63 Langlois, 2018, Clin Chem, 64, 1006, 10.1373/clinchem.2018.287037 Watts, 2020, Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia, Heart Lung Circ., S1443-9506, 31505 González-Juanatey, 2011, Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain: DYSIS-Spain Study, Rev Esp Cardiol., 64, 286, 10.1016/j.recesp.2010.10.030 Pedro-Botet, 2014, Atherogenic dyslipidemia: Prevalence and management in lipid clinics, Rev Clin Esp., 214, 491, 10.1016/j.rce.2014.06.001 Mach, 2020, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur Heart J., 41, 111, 10.1093/eurheartj/ehz455 Pichler, 2018, LDL particle size and composition and incident cardiovascular disease in a South-European population: The Hortega-Liposcale Follow-up Study, Int J Cardiol., 264, 172, 10.1016/j.ijcard.2018.03.128 Carmena, 2004, Atherogenic lipoprotein particles in atherosclerosis, Circulation., 109 Fruchart, 2008, The residual risk reduction initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia, Am J Cardiol., 102, 1K, 10.1016/j.amjcard.2008.10.002 Millán Núnez-Cortés, 2014, Use of expert consensus to improve atherogenic dyslipidemia management, Rev Esp Cardiol., 67, 36 Kotseva, 2009, EUROASPIRE.III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries, Eur J Cardiovasc Prev Rehabil., 16, 121, 10.1097/HJR.0b013e3283294b1d Anderson, 2013, 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult, Can J Cardiol., 29, 151, 10.1016/j.cjca.2012.11.032 Grundy, 2018, AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task force on clinical practice guidelines, J Am Coll Cardiol., 73, e285, 10.1016/j.jacc.2018.11.003 Evolución del riesgo cardiovascular en la población andaluza: 1992-2007. Estudio DRECA 2. Sevilla, España: Dirección General de Salud Pública y Participación, Informes técnicos, Servicio Andaluz de Salud, Consejería de Salud; 1999. Nordestgaard, 2016, Lipoproteínas ricas en triglicéridos y enfermedad cardiovascular aterosclerótica: nuevos conocimientos de epidemiología, genética y biología, Circ Res, 118, 547, 10.1161/CIRCRESAHA.115.306249 Thomsen, 2014, Triglicéridos bajos sin ayuno y mortalidad por todas las causas reducida: un estudio de aleatorización mendeliana, Acta Bioquím Clín Latinoam, 48, 491 De Wolf, 2020, EFLM Task Group on Cardiac Markers. How well do laboratories adhere to recommended guidelines for dyslipidaemia management in Europe? The CArdiac MARker Guideline Uptake in Europe (CAMARGUE) study, Clin Chim Acta., 508, 267, 10.1016/j.cca.2020.05.038 Rasmussen, 2016, Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review, Atherosclerosis., 255, 145, 10.1016/j.atherosclerosis.2016.10.037 Liehn, 2018, Apolipoprotein E in cardiovascular diseases: Novel aspects of an old-fashioned enigma, Arch Med Res., 49, 522, 10.1016/j.arcmed.2018.08.008 Jansen, 2004, La contribución de los factores de riesgo clásicos a la enfermedad cardiovascular en la hipercolesterolemia familiar: datos en 2400 pacientes’, J Intern Med, 256, 482, 10.1111/j.1365-2796.2004.01405.x Alonso, 2014, SAFEHEART Investigators. Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation, J Am Coll Cardiol., 63, 1982, 10.1016/j.jacc.2014.01.063 Ellis, 2019, Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia, J Am Coll Cardiol., 73, 1029, 10.1016/j.jacc.2018.12.037 Mostaza, 2019, Standards for global cardiovascular risk management arteriosclerosis, Clin Investig Arterioscler., 31, 1